Addendum
Cemiplimab (basal cell carcinoma) - Addendum to Commission A21-97
Report documents
-
Addendum
Cemiplimab (basal cell carcinoma) - Addendum to Commission A21-97
Dossier assessment
Indication:
Adult patients with locally advanced or metastatic basal cell carcinoma who were previously treated with a hedgehog signal pathway inhibitor and show disease progression or intolerance to it during this treatment
Result of dossier assessment:
Unchanged after addendum:
Added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
2022-01-20 A G-BA decision was published.
Project details
- Project no.
- A21-161
- Commission
- Commission awarded on 07.12.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Cemiplimab (basal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed